Charles River Laboratories International (CRL) has seen a flurry of action from investment firms and analysts. Notably, institutional investors including
Norris Perne & French LLP MI and Fifth Third Bancorp are reported to have sold a substantial number of shares, while
Veracity Capital LLC has made new acquisitions in the company. Meanwhile, some analysts have lowered their stock holdings, such as
Janney Montgomery Scott LLC, due to added risk from CRL's debt profile. Amidst these transactions,
Charles River Laboratories has made key announcements - it will present its strategy direction for 2025 and unveil a new
biotech incubator program. Despite this, challenges loom, with CRL stock underperforming compared to competitors and reaching a new 52-week low. Its fourth-quarter earnings and 2025 guidance releases are much anticipated, but there's concern about a weak guidance. Additionally,
William Blair downgraded CRL to Market Perform and
The Goldman Sachs Group issued a pessimistic forecast for the stock. Charles River Laboratories is also set to collaborate with Akron Bio to enhance operations.
Charles River Laboratories International CRL News Analytics from Thu, 06 Jun 2024 07:00:00 GMT to Sat, 01 Feb 2025 12:18:10 GMT -
Rating -8
- Innovation 3
- Information 7
- Rumor -5
